CD21, also known as complement receptor type 2 (CR2), is a surface protein found primarily on B cells and follicular dendritic cells that serves as a critical bridge between the body’s fast-acting innate immune defenses and the slower, more precise adaptive immune response. It is perhaps best known clinically for two things: it is the receptor that Epstein-Barr virus uses to break into cells, and its expression level on B cells has become a valuable marker for diagnosing and classifying a growing list of diseases, from lymphomas to autoimmune conditions to primary immunodeficiencies. The biology behind this single molecule turns out to touch a surprising number of medical fields.
What CD21 Actually Does
CD21 is a glycoprotein that sits on the outer surface of cells and acts as a docking station for several different molecules. Its most important job involves grabbing hold of fragments of a protein called C3, which is part of the complement system. When the complement system tags a pathogen or foreign substance, C3 breaks down into smaller pieces (iC3b, C3dg, and C3d) that stick to the surface of that target. CD21 recognizes and binds to those C3 fragments, essentially reading the tags left behind by the innate immune system and passing the information along to the adaptive immune system.
On B cells, CD21 does not work alone. It forms a co-receptor complex with two other surface proteins, CD19 and CD81. When this co-receptor engages a C3d-tagged antigen at the same time the B cell receptor recognizes the antigen itself, the signal the B cell receives is dramatically amplified. The threshold for B cell activation drops by several orders of magnitude, meaning the cell needs far less stimulation to spring into action.
1PubMed Central. Uncoupling CD21 and CD19 of the B-cell coreceptor This co-stimulation mechanism is why CD21 matters so much to vaccine responses and overall immune competence: without it, the immune system has a much harder time mounting a strong antibody response, especially to weakly immunogenic targets.
Beyond C3 fragments, CD21 also binds to CD23 (the low-affinity IgE receptor) and to interferon-alpha, a cytokine involved in antiviral defense. These additional binding partners hint at the molecule’s involvement in allergic responses and viral immunity, though the interaction with C3 fragments remains the best studied and most clinically relevant.
2PubMed. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)CD21 on Follicular Dendritic Cells
B cells get most of the attention in discussions of CD21, but follicular dendritic cells (FDCs) are the other major cell type that expresses it. FDCs live in the germinal centers of lymph nodes and spleen, and their job is to capture antigens and display them to B cells over long periods. They do this by trapping immune complexes and complement-coated material through receptors like CD21 and CD35, holding those antigens on their surface so that B cells cycling through the germinal center can sample them repeatedly.
3PubMed. Follicular dendritic cells: origin, function, and different disease-associated patternsThis antigen-retention function is essential for generating high-affinity antibodies. B cells that produce a slightly better-fitting antibody survive in the germinal center, while those with worse-fitting antibodies die off. The FDCs act as the selection committee, constantly re-presenting the antigen so the immune system can refine its antibody response. When pathologists stain tissue for CD21, the pattern of FDC meshworks they see reveals the architecture of these germinal centers, which turns out to be diagnostically powerful in several types of cancer.
The Epstein-Barr Virus Gateway
Epstein-Barr virus (EBV) infects the vast majority of people worldwide and is linked to mononucleosis, several cancers, and possibly multiple sclerosis. The virus gains entry to B cells by binding its major surface glycoprotein, gp350, directly to CD21.
4PubMed. Epstein-Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection This binding not only opens the door for viral entry but also activates resting B cells through an intracellular signaling pathway, essentially co-opting the cell’s own activation machinery to facilitate infection.
For years, researchers assumed EBV infected T cells through an entirely different mechanism, since T cells were thought not to express CD21. But more recent work demonstrated that T cells can in fact express CD21, and the virus uses the same gp350-to-CD21 interaction to enter them. When researchers knocked out CD21 in a T cell line using gene editing, EBV could no longer get in.
5PubMed Central. CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells This finding expanded the understanding of how EBV establishes its lifelong presence in the body and why certain EBV-associated T cell lymphomas develop.
Pathogen Trapping on Follicular Dendritic Cells
The ability of FDCs to capture complement-coated material through CD21 is normally a feature, not a bug. But certain pathogens exploit it. HIV, for example, becomes coated with complement proteins in the bloodstream. When these opsonized viral particles reach lymph nodes, FDCs trap them through CD21 much as they would trap any other immune complex.
6PubMed Central. Follicular Dendritic Cells Retain Infectious HIV in Cycling Endosomes The trouble is that these FDC-retained viral particles can remain infectious, creating a long-lived reservoir within the lymph node. This reservoir is shielded from some immune surveillance and may contribute to the difficulty of clearing HIV from the body. The same CD21-mediated trapping mechanism that normally helps refine antibody responses becomes, in this context, a hiding spot for the virus.
CD21 in Lymphoma Diagnosis
In surgical pathology, CD21 immunostaining is one of the standard tools for evaluating lymphomas. The stain highlights FDC meshworks within tumors, and the patterns these meshworks form can help pathologists tell apart lymphoma types that otherwise look similar under the microscope.
A good example is distinguishing cutaneous follicular lymphoma from marginal zone lymphoma. Both can appear as clusters of abnormal B cells in the skin, but their FDC architecture differs. In a study of these tumors, CD21 staining revealed three distinct patterns of FDC meshworks in marginal zone lymphomas: reactive germinal centers, colonized follicles (where tumor cells had moved into pre-existing follicles), and expanded meshworks overtaken by tumor cells. These patterns were quite different from what was seen in follicular lymphoma, where CD21-negative interfollicular zones contained the neoplastic cells. The combination of CD21 with a few other markers allowed reliable distinction between the two.
7PubMed. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classificationIn nodal marginal zone lymphoma, a study of 51 cases found that CD21 staining highlighted disrupted FDC meshworks in about 71% of cases and prominent intrafollicular nests of neoplastic cells in about 27%.
8American Journal of Clinical Pathology. Immunoarchitectural Patterns in Nodal Marginal Zone B-Cell Lymphoma: A Study of 51 Cases These disrupted meshwork patterns are a telltale sign that the normal germinal center architecture has been overtaken by tumor, and they help pathologists distinguish marginal zone lymphoma from reactive lymphoid tissue and from other low-grade lymphomas.
Follicular Dendritic Cell Sarcoma
Follicular dendritic cell sarcoma is a rare cancer arising from the FDCs themselves. Because it is uncommon and can mimic other tumors histologically, diagnosis depends heavily on immunohistochemistry. CD21 is one of the key markers pathologists reach for, alongside CD23, CD35, clusterin, and others. The challenge is that tumor cells in FDC sarcoma frequently lose expression of individual markers, so a broad panel is needed. A tumor that stains positive for CD21 and one or two other FDC markers in the right clinical and histological context strongly supports the diagnosis.
9PubMed Central. Follicular dendritic cell sarcoma Without these markers, FDC sarcoma can be mistaken for more common cancers like carcinoma or melanoma, which would lead to entirely different treatment plans.
CD21-Low B Cells in Autoimmunity and Immunodeficiency
Some of the most active clinical research involving CD21 focuses not on whether cells express it, but on how much they express. A population of B cells with unusually low CD21 surface levels, often written as CD21lo or CD21lo/neg, has emerged as a meaningful marker in several disease contexts.
In systemic lupus erythematosus (SLE), researchers identified an expanded population of B cells with an activated phenotype characterized by high CD19 expression and low CD21.
10PubMed. A new CD21low B cell population in the peripheral blood of patients with SLE These cells appear to be chronically activated and are thought to contribute to the autoantibody production that drives lupus flares. Their presence in the blood can serve as a marker of disease activity.
A similar expansion of CD21-low B cells shows up in common variable immunodeficiency (CVID), one of the most frequent primary immunodeficiency disorders. Patients with CVID who develop autoimmune complications such as autoimmune blood cell destruction and enlarged spleens tend to have a larger pool of CD19-high, CD21-low B cells compared to CVID patients without these complications. The size of this CD21-low B cell pool has been proposed as a clinical marker to identify CVID patients at higher risk for autoimmune problems.
11PubMed. Expansion of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopeniaMore recently, researchers have connected these CD21-low B cells to a broader phenomenon driven by the transcription factor T-bet. T-bet drives the formation of a B cell subset characterized by high CD11c expression and low CD21, sometimes called age-associated B cells because they accumulate with aging. These cells share features across autoimmune diseases, chronic infections, and normal immunosenescence.
12PubMed Central. Human T-bet governs the generation of a distinct subset of CD11c(high)CD21(low) B cells Understanding this T-bet-driven pathway may eventually help explain why autoimmune diseases become more common with age and why chronic infections can trigger autoimmune phenomena.
Genetic CD21 Deficiency
Complete loss of CD21 due to genetic mutations is exceptionally rare, but the handful of reported cases have been instructive. One well-characterized patient was a 28-year-old man who presented with recurrent infections, low antibody levels (hypogammaglobulinemia), and reduced class-switched memory B cells. His B cells had no detectable CD21 on their surface, and genetic testing revealed compound mutations in the CD21 gene. Without CD21, his B cells could not bind C3d-containing immune complexes, and the normal co-stimulatory boost from complement tagging was completely absent. His responses to protein vaccines were preserved, but his response to polysaccharide vaccines was moderately impaired.
13PubMed. Genetic CD21 deficiency is associated with hypogammaglobulinemiaThis case illustrates what CD21 contributes in practical terms. The immune system can still generate some antibody responses without it, particularly against protein antigens that are inherently more immunogenic. But the margin for error narrows. Polysaccharide antigens, which are already harder for the immune system to recognize, suffer more when the CD21 co-stimulatory boost is missing. Variations or deletions in the CD21 gene have also been associated with susceptibility to autoimmune and inflammatory conditions in both human and mouse studies, reinforcing the idea that this receptor plays a balancing role, helping the immune system respond appropriately without tipping into self-attack.
14PubMed. The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)Soluble CD21 as a Blood Biomarker
CD21 is not only a surface molecule. A soluble form (sCD21) is released into the bloodstream when a metalloprotease enzyme clips the entire outer portion of CD21 off the cell surface. This shedding process happens normally, and healthy people have measurable levels of sCD21 in their serum.
15Immune System. Soluble CD21: From Shedding to AutoimmunityThe soluble form retains the ability to bind to the same ligands as its membrane-anchored parent, including C3 fragments and CD23. When sCD21 binds to CD23 on monocytes, it triggers signaling pathways that ramp up inflammation, including the release of proinflammatory cytokines and increased expression of molecules involved in antigen presentation.
16PubMed. Functional properties of soluble CD21 In other words, sCD21 is not just an inert byproduct of shedding; it has active signaling capabilities that may be relevant to allergic and inflammatory disorders.
Clinically, sCD21 levels in the blood shift in a number of diseases. Levels are altered in various viral infections, B cell leukemias, and autoimmune disorders compared to healthy individuals.
17Immune System. Soluble CD21: From Shedding to Autoimmunity Whether sCD21 ultimately proves useful as a standalone diagnostic or monitoring biomarker remains an open question, but the pattern of changes across different diseases suggests it reflects the level of B cell turnover and immune activation in the body.
CD21-Targeted Complement Therapy
One of the more creative applications of CD21 biology has nothing to do with diagnosing disease. Researchers realized that because CD21 naturally homes to sites where complement is being activated (by binding the C3 fragments deposited there), a fragment of CD21 could be used as a targeting device to deliver complement-inhibiting drugs exactly where they are needed. The idea is simple: fuse a piece of CR2 that recognizes C3 breakdown products to a complement-inhibiting protein, and the resulting molecule will concentrate at inflamed tissue rather than floating around the whole body.
Early proof-of-concept work showed that fusion proteins built this way were up to 20-fold more effective at protecting cells from complement damage compared to untargeted versions of the same inhibitor.
18JCI Insight. Complement receptor 2–mediated targeting of complement inhibitors to sites of complement activation In a mouse model of intestinal ischemia-reperfusion injury, a CR2-targeted complement inhibitor required a 10-fold lower dose than a systemic (untargeted) inhibitor to achieve equivalent protection against both local and remote organ injury.
19JCI Insight. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infectionThis approach has been extended to more complex constructs. One fusion protein, called TT32, links a CR2-derived targeting fragment to a portion of complement receptor 1 (CR1) that can shut down complement activation through both the classical and alternative pathways. In mouse models of arthritis, TT32 prevented disease development, demonstrating that the CR2-targeting strategy can work across multiple types of complement-driven tissue injury.
20PubMed Central. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models The appeal is that by concentrating the drug at the site of inflammation, you could potentially treat complement-mediated conditions while leaving the rest of the complement system intact to fight infections. Broader complement inhibition, by contrast, carries the risk of leaving the patient vulnerable to bacterial infections.
CD21 in the Tumor Microenvironment
An emerging area of interest involves CD21 in tertiary lymphoid structures (TLS), which are organized clusters of immune cells that can form inside solid tumors. TLS resemble the germinal centers of lymph nodes and can include FDCs, B cells, and T cells. Their presence in tumors is often associated with better outcomes, because they suggest the immune system is mounting an organized local response against the cancer. However, the picture is not always straightforward. In hepatocellular carcinoma, a high proportion of CD21-positive B cells within these structures was associated with worse overall survival, not better.
21Lab Investigation. Lymphocyte Function in Tertiary Lymphoid Structures Predicts Hepatocellular Carcinoma Outcome This counterintuitive finding suggests that not all B cells within TLS are doing the same thing: CD21-positive B cells in this setting may represent a population that is promoting immune tolerance or supporting the tumor rather than attacking it. The function of immune cells in the tumor microenvironment often depends on context, and CD21 expression is turning into a useful way to parse that complexity.